Angiotech Pharmaceuticals, a medical device and specialty pharmaceutical company, has entered into an exclusive five year distribution agreement with B Braun for its proprietary Quill SRS product line in the UK Ireland, and France.

William Hunter, president and CEO of Angiotech, said: “We are very excited and proud to have one of the companies in wound closure partner with Angiotech to facilitate the continued acceptance of Quill SRS in these critical European countries.

“Having a company such as B Braun, with its long legacy of technology, join us as one of our European partners further validates Quill SRS’s market potential as a transformational technology in the surgical market.”

Miguel Pablo, vice president, marketing, sales and regulatory affairs for the closure technologies unit at B Braun Group, said: “We are very much looking forward to including the Quill SRS knotless suturing system in our comprehensive Closure Technologies portfolio and start redefining wound closure.

“Such barbed monofilament sutures fit very well with our global monofilament sutures campaign, and we are convinced that it will be a major breakthrough for our organisation in these markets. With this agreement, we proudly strengthen our strategic partnership with Angiotech.”